Licensing status

Publication and contact information



Integrin a4b1 (CD49D/CD29)

Human and mouse studies suggest inhibiting integrin a4b1 could help prevent metastasis. In patient samples, integrin a4b1 was expressed on 75% of lymphatic vessels from metastatic breast cancer samples and on 50% of lymphatic vessels from nonmetastatic breast cancer samples but at low levels in healthy samples. In mice with Lewis lung carcinoma, melanoma or pancreatic carcinoma cells, anti-integrin a4b1 antibodies decreased metastasis compared with control antibodies. Next steps are to develop a human or humanized anti-integrin a4b1 antibody for imaging lymph nodes associated with cancer and for therapeutic blockade of lymphangiogenesis and metastasis.

SciBX 6(22); doi:10.1038/scibx.2013.540
Published online June 6, 2013

Therapeutic targeting and diagnostic analysis of vascular integrin a4b1 patented; patent application filed for lymph node-specific findings; available for licensing

Garmy-Susini, B. et al. Proc. Natl. Acad. Sci. USA; published online
May 13, 2013;
Contact: Judith Varner, University of California, San Diego, La Jolla, Calif.